[Infostock Daily = Reporter Kim Jong Hyo] Hanmi Pharmaceutical reported a 54% year-on-year decline in consolidated operating profit of 10.6 billion won in the second quarter of 2020. Sales for the same period decreased by 10% to 243.4 billion won and net profit reached 5.8 billion won.
Except for its affiliates, Hanmi Pharmaceutical recorded 215.6 billion won in sales in the second quarter and 18.8 billion won in operating profit, up 7% from the same period last year. On the other hand, Beijing Hanmi Pharmaceuticals posted 27.1 billion won in sales, down 52% from the same period last year. Both operating and net income turned into deficits.
Sales of major self-developed products such as Hanmi Pharm's flagship product 'Amosartan Family' sales amounted to 28.9 billion won, 'Palpal' 11.3 billion won, and 'Esomezol' 9.9 billion won. The dyslipidemia complex 'Rosuzet' sold 24.1 billion won, up 21.6% from the same period last year.
Reporter Kim Jong Hyo kei1000@infostock.com
